{"nctId":"NCT00152516","briefTitle":"Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures","startDateStruct":{"date":"2004-10"},"conditions":["Epilepsy, Partial"],"count":255,"armGroups":[{"label":"Levetiracetam","type":"EXPERIMENTAL","interventionNames":["Drug: levetiracetam (LEV)"]}],"interventions":[{"name":"levetiracetam (LEV)","otherNames":["Keppra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pediatric patients with partial onset seizures, with 1 to 2 anti-epileptic drugs (AEDS), with participation in previous levetiracetam pediatric studies (N01009 or N01103) or direct enrollment, for whom levetiracetam treatment will be of possible benefit\n\nExclusion Criteria:\n\n* Patients on a ketogenic diet\n* Seizures too close together to accurately count\n* Pseudoseizures\n* Status epilepticus 1 month prior Visit 1\n* Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease will be excluded from the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change (Reduction) of Partial (Type I) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.","description":"Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change (Reduction) of Total (Type I, II, III) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.","description":"Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Change (Reduction) From Baseline in Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period","description":"Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Change (Reduction) From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period","description":"Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Partial Seizure (Type I) Responder Rate (Percent) During the Up-titration/Conversion Phase and by Visit During the Maintenance Phase","description":"The responder rate is defined as the number of responders. A responder is a patient with a 50% or greater change (reduction) in partial seizure frequency per week.\n\nNote: Rates were reported as percentages.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)","description":"For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)","description":"For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)","description":"For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)","description":"For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Seizure (Type I, II, III) Continuously Seizure Free During the Maintenance Period","description":"The measure description is the product limit adjusted percent of subjects seizure free starting from the beginning of the Maintenance Period.\n\nThe up-titration period is the up to 6 week period of increasing dose prior to the Maintenance Period. The Maintenance Period is the period of stable dosing, subsquent to the up-titration period, which could last from 42 to 48 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With Each Seizure Type During the Evaluation Period","description":"Type I Seizure is a partial onset Seizure (see International League Against Epilepsy definitions).\n\nType II Seizure is a Generalized Seizure (see International League Against Epilepsy definitions).\n\nType III Seizure is a Unknown Seizure Type (see International League Against Epilepsy definitions).\n\nA subject could experience more than one seizure type.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator Global Evaluation Scale","description":"There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Parent/Guardian Global Evaluation Scale","description":"There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject (>=8 Years Old) Global Evaluation Scale","description":"There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Leiter-R Associated Memory (AM) Memory Screen Composite Score Change From Baseline to Visit 5 (Week 24) and Visit 7 (Week 48) (4 to 16 Year Olds)","description":"The Leiter-R AM battery has 10 subtests. The raw scores of the subtests are converted into scaled scores. Six composite scores are constructed from the 10 subtest scaled scores. The Memory Screen is one of them. It is composed of 2 subtests the Associated Pairs and Forward Memory. The sum of the Associated Pairs and Forward Memory subtest scaled scores are converted into a Memory composite score normally distributed with a mean and standard deviation of 100 (±15). Higher scores and positive changes from baseline are better. The range of the Memory Screen composite score is 44 to 155.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"12.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"15.3"}]}]}]},{"type":"SECONDARY","title":"Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Olds)","description":"This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Olds)","description":"This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Old)","description":"This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Old)","description":"This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":255},"commonTop":["Pyrexia","Upper respiratory tract infection","Vomiting","Nasopharyngitis","Diarrhoea"]}}}